SEOUL — Rokit Healthcare, led by CEO Seok-hwan Yoo, is intensifying its drive to capture global leadership in AI-powered regenerative medicine, backed by a massive investment roadmap totaling 64.5 billion KRW (approximately $47-48 million USD).

The comprehensive financial and operational strategy spans six major pillars: skin regeneration, cartilage regeneration, kidney regeneration, hair restoration, artificial intelligence forecasting, and longevity management. Funding and project execution are slated to roll out progressively through 2028.

Rather than developing isolated regenerative treatments, the company’s core strategy centers on establishing a unified medical platform. This platform aims to predict disease onset risks, proactively manage health vulnerabilities, and restore the biological structure and functionality of damaged human tissues and organs.

Beginning with its proven skin regeneration technologies, Rokit is sequentially expanding into cartilage and kidney treatments, advancing hair restoration R&D, and integrating AI-driven predictive health models to cement its status as a world leader in AI regeneration.

Pioneering the World’s First Integrated PPR Medical Platform

While conventional healthcare primarily focuses on symptom management through medication or surgery after a disease manifests, Rokit Healthcare is seeking a paradigm shift. The firm is fusing artificial intelligence, 3D bioprinting, and patient autologous (self-derived) tissue technologies.

The enterprise's comprehensive ecosystem is structured around three core pillars:

Predict: Utilizing advanced AI analytic frameworks, such as AI-Totalis 35 and AI Kidney Monitoring, to forecast health risks, track organ function shifts, and back personalized clinical decision-making.
Prevent: Leveraging predictive analytics to manage health hazards preemptively and pairing insights with tailored healthcare services to extend healthy life expectancy.
Regenerate: Applying AI-customized designs, 3D bioprinting, and patient-derived tissues to rebuild the architecture and function of damaged tissues and organs.
By seamlessly connecting predictive diagnostics with regenerative therapeutics, Rokit aims to deliver a continuous, end-to-end medical service chain.

Fast-Tracking Commercialization Across Four Core Organ Regeneration Pillars

Rokit is simultaneously driving clinical validation and commercial expansion across four critical fields:

Skin Regeneration: Serving as the vanguard of global commercialization, the company is building on its established success in treating chronic, intractable wounds such as diabetic foot ulcers, expanding into major worldwide medical markets.
Cartilage Regeneration: Having entered the critical phase of clinical visibility, current trials involve roughly 80 patients, with a target to hit a total enrollment of 104 participants soon. Subsequent plans include applying for domestic advanced regenerative medicine clinical programs to establish a springboard for international regulatory approvals and broader commercial rollouts.
Kidney Regeneration: Positioned as a next-generation growth engine, this initiative focuses on an omentum-based regenerative patch fused with AI and 3D bioprinting. Rokit plans to apply for domestic advanced regenerative medical trial approvals to clinically validate the technology's potential to preserve renal function and delay dialysis.
Hair Restoration & AI Forecasting: Alongside kidney and cartilage initiatives, the firm is heavily investing in hair regeneration research and longevity platform scaling to complete its holistic ecosystem.

Building a Patient-Centric Medical Ecosystem

The 65.4 billion KRW mid-to-short-term investment blueprint prioritizes kidney regeneration clinical development, longevity platform enhancement, global cartilage trials, skin therapy expansion, hair regeneration R&D, and AI predictive analytics.

Rokit Healthcare has designated 2026 and 2027 as pivotal transformation windows to establish its global AI regenerative medicine platform before systematically scaling its services.

Ultimately, the company aims to move beyond the limitations of traditional R&D or licensing-out models. By deploying solutions directly into global clinical settings, Rokit seeks to generate sustainable, recurring revenue streams as a platform enterprise.

"Powered by our AI hyper-personalized regenerative medicine platform, we will challenge ourselves to become the undisputed global number-one company in the regenerative medicine industry," a Rokit Healthcare representative stated.

[ⓒ Global Economic Times. 무단전재-재배포 금지]